GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytomX Therapeutics Inc (NAS:CTMX) » Definitions » 5-Year Yield-on-Cost %

CytomX Therapeutics (CytomX Therapeutics) 5-Year Yield-on-Cost % : 0.00 (As of Jun. 01, 2024)


View and export this data going back to 2015. Start your Free Trial

What is CytomX Therapeutics 5-Year Yield-on-Cost %?

CytomX Therapeutics's yield on cost for the quarter that ended in Mar. 2024 was 0.00.


The historical rank and industry rank for CytomX Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:



CTMX's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.75
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of CytomX Therapeutics's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, CytomX Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytomX Therapeutics's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytomX Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where CytomX Therapeutics's 5-Year Yield-on-Cost % falls into.



CytomX Therapeutics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of CytomX Therapeutics is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

CytomX Therapeutics  (NAS:CTMX) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


CytomX Therapeutics 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of CytomX Therapeutics's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


CytomX Therapeutics (CytomX Therapeutics) Business Description

Traded in Other Exchanges
Address
151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Executives
Marcia Belvin officer: SVP, Chief Scientific Officer C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., STE. 400, SOUTH SAN FRANCISCO CA 94080
Christopher Ogden officer: SVP, Finance and Accounting C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Jeffrey B Landau officer: Chief Financial Officer C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Lloyd A Rowland officer: General Counsel AMYLIN PHARMACEUTICALS INC, 9360 TOWNE CENTRE DR, SAN DIEGO CA 92121
Sean A. Mccarthy director, officer: President and CEO 343 OYSTER POINT BLVD., SUITE 100, SOUTH SAN FRANCISCO CA 94080
Yu-waye Chu officer: Chief Medical Officer FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121
Elaine V Jones director C/O TARGACEPT, INC., 200 EAST FIRST STREET, SUITE 300, WINSTON-SALEM NC 27101
Amy C. Peterson officer: EVP, Chief Development Officer C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Carlos Campoy officer: Chief Financial Officer 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Alison L. Hannah officer: Chief Medical Officer 12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
Alan Ashworth director C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., STE. 400, SOUTH SAN FRANCISCO CA 94080
Bvf I Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104